Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Ventilatory Modes

Ventilatory Modes

Mechanical ventilators are life-saving devices that support or replace spontaneous breathing. They deliver breaths to patients through varying methods known as ventilator modes. Understanding these modes is critical for healthcare providers managing patients with respiratory failure.
There are three ventilatory modes: full support, partial support, and spontaneous. These are described below.
Full Support Modes
Full support modes include controlled mechanical ventilation, continuous mandatory...

Mechanical Ventilation II: Invasive Ventilation

Mechanical Ventilation II: Invasive Ventilation

Ventilators are essential medical equipment used to aid patients with respiratory difficulties. Their primary function is to assist or replace spontaneous breathing by providing mechanical ventilation. There are two general classes of mechanical ventilators: negative-pressure and positive-pressure ventilators.
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Limited surgical approach for explanting the HeartMate II left ventricular assist device after myocardial recovery.

The Journal of thoracic and cardiovascular surgery·2008

Same author

Clinical performance with the Levitronix Centrimag short-term ventricular assist device.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2006

Same author

Association of improved cardiac function in donors with C34T mutation of the AMP deaminase 1 gene.

Nucleosides, nucleotides & nucleic acids·2005

Same author

AMPD1 C34T mutation selectively affects AMP-deaminase activity in the human heart.

Nucleosides, nucleotides & nucleic acids·2005

Same author

Incidence and clinical management of life-threatening left ventricular assist device failure.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2004

Same author

Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy.

Circulation·2004

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Left ventricular assist devices.

¹Royal Brompton and Harefield NHS Trust, Harefield, Middlesex UB9 6JH, UK. e.birks@imperial.ac.uk

Heart (British Cardiac Society)

|July 21, 2009

Summary

This summary is machine-generated.

Left ventricular assist devices (LVADs) are life-saving for advanced heart failure. Myocardial recovery is possible, enabling device removal and avoiding transplantation.

More Related Videos

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Related Experiment Videos

Last Updated: Jun 21, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Area of Science:

Cardiology
Medical Devices
Heart Failure Management

Background:

Advanced heart failure necessitates life-saving interventions.
Left ventricular assist devices (LVADs) are increasingly used for deteriorating patients.
Donor heart scarcity drives demand for alternative therapies like LVADs.

Purpose of the Study:

To explore the evolving role and indications of LVADs in advanced heart failure.
To highlight LVADs as a bridge to recovery and destination therapy.
To discuss technological advancements and improved outcomes with LVADs.

Main Methods:

Review of current literature and clinical evidence on LVADs.
Analysis of LVADs' impact on myocardial function and patient survival.
Examination of evolving indications: bridge to transplantation, bridge to recovery, and destination therapy.

Main Results:

LVAD support can lead to myocardial recovery, enabling device explantation.
Bridge to recovery is an expanding indication, avoiding transplantation and immunosuppression.
Destination therapy is a growing role for LVADs as a lifelong alternative.

Conclusions:

LVAD technology is advancing, improving survival and reducing complications.
LVADs offer versatile solutions for advanced heart failure, from temporary support to permanent therapy.
The future of LVADs includes wider application in bridge to recovery and destination therapy.